### **VPI/00-102 CON DIV3 US**

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.:

10/688,613

Confirmation No.:

2448

Filing Date:

October 17, 2003

Examiner:

Deborah C. Lambkin

Group Art Unit:

1626

Applicants:

Michael Hale et al.

For:

PYRAZOLE COMPOSITIONS USEFUL AS INHIBITORS OF ERK

Cambridge, Massachusetts
July 29, 2005

Director of the U.S. Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450

## TERMINAL DISCLAIMER UNDER 37 C.F.R. § 1.321(b) and (c)

Dear Sir.

VERTEX PHARMACEUTICALS INCORPORATED, a corporation organized and existing under the laws of the Commonwealth of Massachusetts, having an office and place of business at 130 Waverly Street, Cambridge, Massachusetts 02139-4242 ("VERTEX PHARMACEUTICALS INC."), represents that it is the assignee of record of the entire right, title and interest, by assignment, of the following:

### RECEIVED **CENTRAL FAX CENTER** JUL 2 9 2005

Applicants:

Michael Hale et al.

Application No.: 10/688,613

#### FEE FOR ADDITIONAL CLAIMS

- A fee for additional claims is not required. [X]
- A fee for additional claims is required. []

The additional fee has been calculated as shown below:

	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR			PRESENT EXTRA	RATE		ADDITIONAL FEES	
TOTA	L CLAIMS	24	-	24	* =	x	\$ 50	=	\$	0
INDEI CLAI	PENDENT MS	1	-	3	** =	. <b>x</b>	\$200	=	\$	0
	PRESENTA			м		+	\$360	=	\$	
*	If less than 20, insert 20. If less than 3, insert 3.					TOTAL			<u>\$_0</u>	

- A check in the amount of \$\_\_ in payment of the filing fee is transmitted herewith.
- Please charge \$\_\_\_ to Deposit Account No. 50-0725 in payment of the filing [] fee. A duplicate copy of this transmittal letter is transmitted herewith.
- The Director is hereby authorized to charge payment of any additional filing [X]fees required under 37 C.F.R. § 1.16, in connection with the paper(s) transmitted herewith, or credit any overpayment of same, to deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.

## RECEIVED **CENTRAL FAX CENTER** JUL 2 9 2005

Applicants:

Michael Hale et al.

Application No.:

10/688.613

#### **EXTENSION FEE**

- The following extension is applicable to the Response filed herewith; [] [X] \$120.00 extension fee for response within first month pursuant to 37 C.F.R. § 1.136(a); [] \$450.00 extension fee for response within second month pursuant to 37 C.F.R. § 1.136(a); [X] \$1,020.00 extension fee for response within third month pursuant to 37 C.F.R. § 1.136(a); [] \$1,590.00 extension fee for response within fourth month pursuant to 37 C.P.R. § 1.136(a); [] \$2,160.00 within fifth month pursuant to 37 C.F.R. § 1.136(a).
- [] A check in the amount of [] \$120.00; [] \$450.00; [] \$1,020.00; [] \$1,590.00; [] \$2,160.00 in payment of the extension fee is transmitted herewith.
- Please charge the extension fee in the amount of [] \$120.00; [] \$450.00; [X] \$1,020.00; [] \$1,590.00; [] \$2,160.00 to Deposit Account No. 50-0725. A duplicate copy of this transmittel letter is transmitted herewith.
- [X]The Director is hereby authorized to charge payment of any additional fees required under 37 C.F.R. § 1.17 in connection with the paper(s) transmitted herewith, or to credit any overpayment of same, to Deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.

#### MISCELLANEOUS FEES

[]	Please charge \$	to Deposit Account No. 50-0725 for
----	------------------	------------------------------------

Respectfully submitted,

Karén E. Brown, Reg. No. 43,866

Attorney/Agent for Applicants

Vertex Pharmaceuticals Incorporated

The second secon

130 Waverly Street

Cambridge, Massachusetts 02139

Tel: (617) 444-6168 Fax: (617) 444-6483